a transcription factor that plays major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Heterodimers between E2A and tissue-specific basic helix-loop-helix (bHLH) Dimers bind DNA on E-box motifs: 5'- CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Deletions in E2A have been observed in a subset of pre-B-cell acute lymphoblastic leukemia (B-ALL) cases. Two alternatively spliced human isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: Transcription factor; DNA binding protein
Cellular Component: nucleoplasm; transcription factor complex; protein complex; cytoplasm; nucleus
Molecular Function: protein binding; protein homodimerization activity; DNA binding; sequence-specific DNA binding; protein heterodimerization activity; transcription coactivator activity; bHLH transcription factor binding; mitogen-activated protein kinase kinase kinase binding; chromatin binding; transcription factor binding; transcription factor activity
Biological Process: Peyer's patch development; response to drug; transcription, DNA-dependent; protein stabilization; immunoglobulin V(D)J recombination; B cell lineage commitment; positive regulation of transcription, DNA-dependent; T cell differentiation in the thymus; positive regulation of cell cycle; response to lipopolysaccharide; muscle cell differentiation; regulation of transcription, DNA-dependent; natural killer cell differentiation; B cell differentiation; positive regulation of B cell proliferation; positive regulation of muscle cell differentiation; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; G1 phase of mitotic cell cycle; positive regulation of neuron differentiation; cell development
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.